Purification and characterization of 66-kDa glycoprotein from human breast carcinoma

Cancer Science

Volumn 98, Issue 9, 2007, Pages 1344-1349

  Feng, Renqing ^a   Liu, Xiang ^a   Guo, Zhenquan ^a   Li, Jinfeng ^b  

^a PEKING UNIVERSITY   (China)

^b PEKING UNIVERSITY CANCER HOSPITAL AND INSTITUTE   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; BETA TUBULIN; GLYCOPROTEIN; GLYCOPROTEIN 1D8; UNCLASSIFIED DRUG;

AMINO ACID SEQUENCE; ANIMAL CELL; ARTICLE; BREAST CARCINOGENESIS; BREAST CARCINOMA; CANCER CELL CULTURE; CANCER CLASSIFICATION; CONTROLLED STUDY; CYTOPLASM; HUMAN; HUMAN TISSUE; IMMUNOCYTOCHEMISTRY; IMMUNOHISTOCHEMISTRY; MASS SPECTROMETRY; MOLECULAR MECHANICS; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN METHYLATION; PROTEIN PROTEIN INTERACTION; PROTEIN PURIFICATION; WESTERN BLOTTING;

AMINO ACID SEQUENCE; ANIMALS; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; CELL LINE, TUMOR; FEMALE; GLYCOPROTEINS; HUMANS; MICE; MICE, INBRED BALB C; MOLECULAR SEQUENCE DATA; NEOPLASM PROTEINS; PEPTIDE FRAGMENTS; PROTEIN PRECURSORS; SERUM ALBUMIN; TUMOR MARKERS, BIOLOGICAL;

EID: 34547766595     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/j.1349-7006.2007.00539.x     Document Type: Article

References (15)

1. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2005; 55: 74-108.
2. Alix-Panabieres C, Brouillet JP, Fabbro M et al. Characterization and enumeration of cells secreting tumor markers in the peripheral blood of breast cancer patients. J Immunol Meth 2005; 299: 177-88.
3. Tanaka Y, Amos KD, Fleming TP, Eberlein TJ, Goedegebuure PS. Mammaglobin-A is a tumor-associated antigen in human breast carcinoma. Surgery 2003; 133: 74-80.
4. Kuroki M, Ueno A, Matsumoto H et al. Significance of tumor-associated antigens in the diagnosis and therapy of cancer: An overview. Anticancer Res 2002; 22: 4255-64.
5. Molina R, Jo J, Filella X et al. c-erbB-2, CEA and CA 15.3 serum levels in the early diagnosis of recurrence of breast cancer patients. Anticancer Res 1999; 19: 2551-5.
6. Molina R, Filella X, Alicarte J et al. Prospective evaluation of CEA and CA 15.3 in patients with locoregional breast cancer. Anticancer Res 2003; 23: 1035-41.
7. Climent MA, Segui MA, Peiro G et al. Prognostic value of HER-2/neu and p53 expression in node-positive breast cancer. HER-2/neu effect on adjuvant tamoxifen treatment. Breast 2001; 10: 67-77.
8. Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 1976; 72: 248-54.
9. Yan J, Wang S, Mi JB, Guo ZQ et al. Production and characterization of anti-recombinant human erythropoietin (rhEPO) monoclonal antibody. J Immunoassay Immunochem 2004; 25 (1): 91-101.
10. Molina R, Jo J, Filella X et al. c-erbB-2 oncoprotein, CEA, and CA 15.3 in patients with breast cancer: Prognostic value. Breast Cancer Res Treat 1998; 51: 109-19.
11. Molina R, Jo J, Filella X et al. c-erbB-2 oncoprotein in the sera and tissue of patients with breast cancer. Utility Prognosis Anticancer Res 1996; 16: 2295-300.
12. Ciocca DR, Elledge R. Molecular markers for predicting response to tamoxifen in breast cancer patients. Endocrine 2000; 13: 1-10.
13. Piccart-Gebhart MJ, Procter M, Leyland-Jones B et al. Herceptin Adjuvant (HERA) Trial Study Team. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 2005; 353: 659-72.
14. Kossoy G, Avinoach I, Zusman I, Scheider DP, Ben-Hur H, Elhayany A. Human soluble p66 and p51 tumor-associated antigens promote the suppression of rat mammary tumors in comparison to commercial human albumin. Oncol Rep 2004; 11: 487-91.
15. Tommasi S, Mangia A, Lacalamita R et al. Cytoskeleton and paclitaxel sensitivity in breast cancer: The role of β-tubulins. Int J Cancer 2007; 120: 2078-85.